Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia.
Conclusions: In Medicare patients with CLL/SLL, 1L ibrutinib single agent was associated with total monthly cost savings relative to 1L CIT, driven by lower monthly medical costs that fully offset higher monthly pharmacy costs.
PMID: 33044848 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Leukemia | Lymphoma | Medicare | Research | Study